JPM24, Day 2: BioNTech warns of COVID vaccine sales decline; Alnylam looks to become 'top-tier' biopharma player
Fierce Pharma
JANUARY 3, 2024
As the J.P. | As the J.P. Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024.
Let's personalize your content